MedPath
HSA Approval

TOLUCOMBI TABLET 40MG/12.5MG

SIN15617P

TOLUCOMBI TABLET 40MG/12.5MG

TOLUCOMBI TABLET 40MG/12.5MG

January 24, 2019

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantSINGAPORE PHARMACEUTICAL PRIVATE LIMITED
Licence HolderSINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09DA07

telmisartan and diuretics

Manufacturer Information

SINGAPORE PHARMACEUTICAL PRIVATE LIMITED

Krka, d.d., Novo mesto

Active Ingredients

Hydrochlorothiazide

12.50mg

Hydrochlorothiazide

Telmisartan

40.00mg

Telmisartan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

TOLUCOMBI TABLET 40MG/12.5MG - HSA Approval | MedPath